Vera Therapeutics Inc. reported a net loss of $80.3 million, or $1.26 per diluted share, for the quarter ended September 30, 2025, compared to a net loss of $46.6 million, or $0.85 per diluted share, for the same period in 2024. Net cash used in operating activities during the nine months ended September 30, 2025, was $171.1 million, up from $95.5 million in the previous year. As of September 30, 2025, the company held $497.4 million in cash, cash equivalents, and marketable securities. Vera Therapeutics expects its current funds to be sufficient to support operations through the potential approval and U.S. commercial launch of atacicept and beyond. The company is preparing for a Biologics License Application submission for atacicept for the treatment of IgA nephropathy in adults, expected in the fourth quarter of 2025, with potential FDA approval and U.S. launch in 2026. Vera is also actively enrolling patients in the PIONEER, atacicept monthly dose range finding, and ORIGIN Extend studies.